Renal oncocytoma — a benign kidney tumour

A renal oncocytoma is a benign tumour. It is not cancer, and it is not regarded as spreading to lymph nodes or to other organs the way a kidney cancer can. In that sense it is not dangerous. The care that goes into an oncocytoma is not about the tumour behaving badly — it is about being sure of the label, because scans alone cannot always separate an oncocytoma from a renal cell carcinoma. A large one can occasionally cause a dragging ache or bleed, which is a reason to have it assessed rather than a sign that it has turned into something else.

A true oncocytoma, confirmed on tissue by a pathologist, is not regarded as transforming into renal cell carcinoma. The situation people are really describing when they ask this is different: a mass that looked like an oncocytoma on a scan, or was called an oncocytic neoplasm on a small biopsy sample, is later shown to have been a cancer all along. That is a limitation of the test, not a change in the tumour. It is exactly why a solid kidney mass is characterised carefully on contrast imaging, and why the plan is agreed in a tumour board rather than by one doctor.

Not reliably by imaging alone, and any doctor who tells you otherwise is overstating it. A central star-shaped scar and a spoke-wheel pattern of vessels are the features described with oncocytoma, but chromophobe renal cell carcinoma can show the same picture, and plenty of oncocytomas show neither. What contrast CT or MRI does well is characterise the mass — its size, its blood supply, whether it is confined to the kidney. The separation from cancer is made on tissue: a needle biopsy of the mass, or full pathology after the mass has been removed.

Not automatically. Once the diagnosis is reasonably secure, a small oncocytoma causing no symptoms can be watched with interval imaging, which CION monitors in-house. Removal is considered when the mass is large, when it is causing pain or bleeding, when it is growing in a way that changes the assessment, or when the diagnosis remains uncertain after biopsy. If an operation is the right answer, CION coordinates nephron-sparing partial nephrectomy — including robotic surgery — with specialist urology and uro-oncology teams at partner centres, rather than performing it in-house.

Often, but not always, and the honest answer matters here. A renal mass biopsy takes a needle core from the tumour, and a pathologist looks for the dense, mitochondria-rich cells that define an oncocytoma. NCCN guidance recognises renal mass biopsy as a way to inform the management of a small renal mass. Its limitation is that oncocytoma and chromophobe renal cell carcinoma share features, so a small sample is sometimes reported as an oncocytic neoplasm without a final label. When that happens, the choice is between continued surveillance and removal, and it is discussed with you rather than decided for you.

It means the mass is watched on a planned schedule instead of being treated, and it is an option NCCN recognises for small renal masses. In practice that is a repeat contrast scan at set intervals, kidney function bloods, and a review of whether anything about the mass has changed in character rather than simply in millimetres. Surveillance is a decision, not a delay — you are told what would change the plan before you start, so a scan appointment is never a source of dread. At CION this monitoring is medical-oncology led and arranged in-house.